Hepatology
Article
Bezafibrate eased pruritus in patients with fibrosing cholangiopathies
In all, 45% of bezafibrate recipients had at least a 50% decrease in pruritus on a 10-point visual analog scale, compared with 11% of the placebo...
Article
AGA Clinical Practice Update: How diet and exercise can help manage NAFLD
NAFLD affects approximately 25% of individuals worldwide, but medication, bariatric endoscopy, and surgery are reserved for only a small subset....
Conference Coverage
HCC rates slow in cities, continue to climb in rural areas
Disparities in hepatocellular carcinoma incidence rates between urban and rural areas vary by race/ethnicity.
Conference Coverage
Liver-related deaths decline after Medicaid expansion under ACA
Investment in Medicaid expansions paid off in fewer liver-related deaths and a decrease in racial/ethnic disparities.
Conference Coverage
Liver injury linked to COVID-19–related coagulopathy
Cells that line the liver’s blood vessels produce high levels of factor VIII, a coagulation factor, when they are exposed to interleukin-6, an...
News
Semaglutide shows promise in NASH phase 2 study
The drug “bodes well for further study” in a condition with no FDA approved treatments.
News
Lipid profiles distinguish obese and nonobese NAFLD patients
Distinct lipid combinations showed noninvasive predictive potential for both obese and nonobese nonalcoholic fatty liver disease patients.
News
NAFLD may predict arrhythmia recurrence post-AFib ablation
The presence of nonalcoholic fatty liver disease adds a further modifiable target for preablation medical optimization, researchers say.
News
New CDC guidance for health care personnel exposed to HCV
Baseline testing of the source patient and the HCP should be performed as soon as possible, preferably within 48 hours of exposure.
News
Women suffer less NAFLD but more advanced fibrosis
Compared with men, women have a lower risk of nonalcoholic fatty liver disease, but a higher risk of advanced fibrosis if NAFLD is present.